<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155765</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-2</org_study_id>
    <nct_id>NCT01155765</nct_id>
  </id_info>
  <brief_title>Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis</brief_title>
  <official_title>Prasugrel in Comparison to High Clopidogrel Dose for Inhibition of Platelet Reactivity as Assessed With a Point-of-Care Platelet Function Assay in Patients Undergoing Chronic Hemodialysis Presenting Resistance to the Usual Clopidogrel Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel administration is essential in patients undergoing percutaneous coronary
      intervention, in patients with previous stroke, in patients under chronic hemodialysis via
      fistulae and in patients with chronic atrial fibrillation if coumarin administration is not a
      viable option. Patients with chronic renal failure present lower clopidogrel response
      compared to those with normal renal function. Additionally, hemodialysis via the dialysis
      filter causes a decrease in glycoprotein platelet receptors, potentially associated with
      thienopyridine hyporesponsiveness. Clopidogrel resistant patients as assessed by VerifyNow
      P2Y12(Accumetrics)will be randomized in 1:1 fashion to prasugrel 10mg/day or clopidogrel
      150mg/day. On day 15±2 days a crossover directly to the alternate treatment group will be
      carried out, without an interventing washout period. All patients will undergo platelet
      reactivity assessment, documentation of major adverse cardiac events and documentation of any
      serious adverse events(stroke, bleeding)at day 15 and day 30.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity Units (PRU)assessed by VerifyNow P2Y12(Accumetrics)</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (death, myocardial infarction, revascularization)</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel per os 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel per os 150 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 10 mg/day for 15 days</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 150 mg/day for 15 days</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years old

          2. History of chronic renal failure under hemodialysis for at least 6 months

          3. Under clopidogrel 75mg/day treatment for at least 7 days before randomization

          4. Informed consent obtained in writing

        Exclusion Criteria:

          1. Treatment with other investigational agents (including placebo) or devices within 30
             days prior to randomization or planned use of investigational agents or devices prior
             to the Day 30 visit.

          2. Pregnancy

          3. Breastfeeding

          4. Inability to give informed consent or high likelihood of being unavailable for the Day
             30 follow up.

          5. Malignancy

          6. Acute coronary syndrome or hemodynamic instability within 30 days prior to
             randomization

          7. Requirement for oral anticoagulant prior to the Day 30 visit

          8. Requirement for discontinuation of thienopyridine treatment prior to the Day 30 visit

          9. Treatment with IIb/IIIa inhibitors within 30 days prior to randomization or planned
             administration prior to the Day 30 visit

         10. Known hypersensitivity to prasugrel or clopidogrel.

         11. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal
             bleeding within the previous 6 months.

         12. Other bleeding diathesis, or considered by investigator to be at high risk for
             bleeding on thienopyridine therapy.

         13. Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm,
             arteriovenous malformation, aneurysm).

         14. Thrombocytopenia (&lt;100.000 / μL) at randomization

         15. Known liver failure (bilirubin &gt; 2mg/dl)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>November 15, 2010</last_update_submitted>
  <last_update_submitted_qc>November 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dimitrios Alexopoulos</name_title>
    <organization>Patras University Hospital</organization>
  </responsible_party>
  <keyword>Clopidogrel Resistance</keyword>
  <keyword>prasugrel</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

